Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 4/20 | 0.33 |
| ▸ | VRK1 | Q99986 | 1/20 | 0.30 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3143277 | 0.98 | DPP4 (0.33) | DPP4DPP9BACE1 | |
| Acetic Acid SCHEMBL15094229 | 0.89 | AGBL2 (0.38) | DPP4DPP9BACE1AGBL2 | |
| SCHEMBL1315200 | 0.81 | ALDH1A1 (0.42) | DPP4DPP9BACE1AGBL2ALDH1A1 | |
| SCHEMBL30641925 | 0.79 | DPP4 (0.39) | DPP4DPP9BACE1AGBL2 | |
| SCHEMBL4326940 | 0.79 | DPP4 (0.39) | DPP4DPP9BACE1AGBL2 | |
| Hydrochloric Acid SCHEMBL28375765 | 0.78 | DPP4 (0.39) | DPP4DPP9BACE1AGBL2 | |
| SCHEMBL640600 | 0.76 | NPSR1 (0.41) | DPP4DPP9BACE1 | |
| SCHEMBL31028011 | 0.76 | NPSR1 (0.41) | DPP4DPP9BACE1 | |
| SCHEMBL640601 | 0.76 | NPSR1 (0.41) | DPP4DPP9BACE1 | |
| SCHEMBL640602 | 0.76 | HDAC3 (0.32) | DPP4DPP9BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053235-B2 | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases | Janssen Sciences Ireland Unlimited Company (IE) | 2021-07-06 | — | — | US | disclosed |
| US-20200048242-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-02-13 | — | — | US | disclosed |
| EP-2892893-B2 | 6-AMINO ACID HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2019-10-16 | — | — | EP | disclosed |
| EP-2892893-B1 | 6-AMINO ACID HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2016-12-21 | — | — | EP | disclosed |
| US-9447086-B2 | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-09-20 | — | — | US | disclosed |
| CN-104302626-B | 4, 4-disubstituted-1, 4-dihydropyrimidines and their use as medicaments for the treatment of hepatitis b | 爱尔兰詹森科学公司 | 2016-09-07 | — | — | CN | disclosed |
| US-20160237078-A9 | NOVEL 6-AMINO ACID HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| EP-2800742-B1 | 4,4-DISUBSTITUTED-1,4-DIHYDROPYRIMIDINES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2016-04-06 | — | — | EP | disclosed |
| US-9233933-B2 | 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2016-01-12 | — | — | US | disclosed |
| EP-2892893-A1 | 6-AMINO ACID HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F.HOFFMANN-LA ROCHE AG (CH) | 2015-07-15 | — | — | EP | disclosed |
| US-20070117812-A1 | Dihydropyrimidines | BAYER AKTIENGESELLSCHAFT (DE) | 2007-05-24 | — | — | US | disclosed |
| US-20040167135-A1 | Dihydropyrimidines | BAYER AKTIENGESELLSCHAFT (DE) | 2004-08-26 | — | — | US | disclosed |
| US-6696451-B1 | NITROGEN COMPOUND SUCH AS ETHYL-4-(2-BROMOPHENYL)-2-(3-FLUORO PYRIDIN-2-YL)-6-METHYL-1,4-DIHYDROPYRIMIDIN-5-CARBOXYLATE, USED FOR THE PROPHYLAXIS OF VIRAL DISEASES SUCH AS HEPATITIS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-02-24 | — | — | US | disclosed |
| EP-1080086-B1 | DIHYDROPYRIMIDINES | BAYER AG (DE) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001068642-A1 | DIHYDROPYRIMIDINES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001068647-A1 | MEDICAMENTS AGAINST VIRAL DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001068641-A1 | 6-AMINOALKYL-DIHYDROPYRIMIDINES AND THE USE THEREOF AS MEDICAMENTS AGAINST VIRAL DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001068639-A1 | DIHYDROPYRIMIDINE-5-CARBOXYLIC ACID ESTERS AND USE THEREOF AS MEDICAMENTS AGAINST VIRAL DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
| EP-1080086-A1 | DIHYDROPYRIMIDINES | BAYER AG (DE) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999054326-A1 | DIHYDROPYRIMIDINES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237078-A9 | NOVEL 6-AMINO ACID HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | CYP2B6, HAVCR2, CYP2D6 | DPP4 578/4885DPP9 506/4885BACE1 3718/4885 |
| US-20040167135-A1 | Dihydropyrimidines | DPYD, DHFR, DHPS | DPP4 741/4885DPP9 1022/4885BACE1 2460/4885 |
| US-11053235-B2 | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases | DPYD, TYMP, HAVCR2 | DPP4 267/4885DPP9 589/4885BACE1 1092/4885 |
| US-20200048242-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | DPYD, HAVCR2, TYMP | DPP4 337/4885DPP9 399/4885BACE1 1179/4885 |
| US-20070117812-A1 | Dihydropyrimidines | DPYD, DHFR, TYMP | DPP4 409/4885DPP9 509/4885BACE1 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.